For patients who present with symptoms of cognitive decline, confirming neuronal damage or neurodegeneration is critical for deciding on the proper diagnostic pathway. Testing to detect for neurofilament light chain (NfL), a generic marker of neurodegeneration, is helpful to confirm disease presence and shows promise as an outcome predictor for several neurological conditions.

Propelled by Mayo Clinic-led research, Mayo Clinic Laboratories has implemented a first-in-class test that identifies NfL in blood. Validated to align with CAP and CLIA testing guidelines, the test is a digital ELISA assay that uses the state-of-the art Quanterix Simoa® platform to provide increased sensitivity for detection of NfL in plasma.

Test results that show an elevated NfL concentration confirm presence of a neurodegenerative disease process. This equips providers with increased confidence that their patients are on the correct diagnostic pathway while providing guidance on disease-specific assessments to shorten a patient’s diagnostic journey.

Key testing

NFLC | Neurofilament Light Chain, Plasma

Advantages

• Evaluates NfL concentrations in blood to assess for neuronal damage.
• Provides increased sensitivity through use of digital ELISA testing via the Quanterix Simoa® platform.
• A positive result suggests the presence of a neurodegenerative disease process.
• Results reported in accordance with established age-based reference intervals.